Environmental, Social and Governance Report

The report presents Sino Biopharmaceutical's 2022 ESG strategy around CARE (Cure, Accessible, Relationship and Environmental), supported by a Board ESG Committee and ESG Work Management Committee. It reports 26,272 employees, 543,982.98 MWh of comprehensive energy consumption, 280,010.90 tCO2e total GHG emissions, and a 20% intensity-reduction target by 2025 from 2021. The company also reports RMB108,975,800 environmental-protection investment and RMB66.65 million of public-welfare contributions.